Drug Overdose Deaths Have Declined. Harm Reduction Worked, and Now It’s Being Defunded

May 27, 2026

💊 Don't Trust the Supply. Test It.

As federal harm reduction funding gets pulled back and the drug supply gets more unpredictable, personal testing tools matter more than ever. Reagent kits, fentanyl test strips, and lab analysis put accurate information in your hands.

Shop Drug Test Kits at Bunk Police →

For the first time in over a decade, drug overdose deaths in the U.S. are declining in a sustained way. Fatal overdoses fell roughly 14% in 2025, the third consecutive year of decline and the longest sustained drop in decades. That progress was built by community-based harm reduction work: naloxone distribution, fentanyl test strips, drug checking, syringe services, and treatment expansion, much of it funded by federal grants that have just been cut.

Why Are Drug Overdose Deaths Declining?

The CDC's May 2026 provisional data estimates about 69,973 overdose deaths in the 12 months ending December 2025, down from roughly 80,000 the prior year, and the lowest annual count since 2019. The decline spans nearly every drug category. Fentanyl overdose deaths are down, as well as deaths involving cocaine and methamphetamine. It's a broad-based shift, not a single-substance story.

However, the progress isn't even across the country. Seven states saw overdose deaths increase, with Arizona, Colorado, and New Mexico posting jumps of 10% or more. But the steepest declines (Oregon down 35%, North Carolina down 34%, New York down 32%, Alabama down 28%) are the ones that tell us what's working. The states that invested earliest and most aggressively in harm reduction infrastructure are the ones seeing the biggest gains.

State Change in Overdose Deaths
Oregon Down 35%
North Carolina Down 34%
New York Down 32%
Alabama Down 28%
Arizona, Colorado, New Mexico Up 10%+

The Harm Reduction Evidence Behind the Decline

There's no single explanation for why overdose deaths are declining, but researchers, public health officials, and the people doing the work on the ground point consistently to the same set of factors.

  • Widespread naloxone distribution. Naloxone has been available over the counter since 2023, and community distribution programs have put millions of doses in the hands of people who use drugs, their friends, and their families. Reversals that wouldn't have happened five years ago are happening now.
  • Drug checking and fentanyl test strips. Fentanyl test strips are legal in nearly every state, and drug checking services, from mail-in lab analysis to community-based reagent testing, expanded rapidly over the past three years. People made more informed decisions about what they were consuming, and fewer died as a result.
  • Treatment access. Buprenorphine prescribing restrictions loosened. Methadone access expanded. More people who wanted treatment could get it without months-long waits.
  • Settlement money at work. Billions of dollars from opioid lawsuit settlements have been flowing into state and local prevention and response programs, funding much of the infrastructure above.
  • Supply-side shifts. Some of the decline reflects changes in the drug supply itself, including regulatory action in China that disrupted fentanyl precursor availability.

The Drug Policy Alliance and other harm reduction organizations have been clear about the pattern. The places lowering barriers to care, expanding naloxone, and supporting drug checking are the places seeing lives saved. Medications for opioid use disorder cut overdose risk roughly in half. Community naloxone distribution is one of the strongest predictors of declining deaths. The evidence isn't ambiguous.

Federal Harm Reduction Funding Cuts: What Just Changed

In late April 2026, SAMHSA issued updated guidance restricting federal grant recipients from using funds for fentanyl test strips and other harm reduction supplies, calling them "incompatible with Federal laws." This is the same federal funding that supports much of the community-based infrastructure responsible for the overdose decline.

Many of the programs that distribute test strips, naloxone, and other supplies operate on thin margins. Federal grants aren't a small piece of their budget. For most of these, often volunteer-powered organizations, federal grants are the full budget. The guidance also signals a broader shift in federal drug policy away from harm reduction as a framework.

⚠️ Why This Timing Matters: It's too early to know how this will affect overdose trends. New provisional data won't be available for months, but the timing concerns researchers and frontline workers for a reason. The decline in deaths is closely tied to the expansion of harm reduction infrastructure, and pulling federal support from that infrastructure is the kind of policy shift that has measurable consequences.

Federal Funding May Be Shrinking. The Tools Don't Have To.

Fentanyl test strips, reagent kits, and mail-in lab analysis remain available regardless of which way federal policy shifts. Stock up on the tools that have been driving the decline.

Get Fentanyl Test Strips →

New Drugs in the Supply: Xylazine, Medetomidine, and Nitazenes

On top of the funding shift, the unregulated drug supply continues to evolve. The Center for Forensic Science Research and Education, a federally funded toxicology lab that helps run the national early warning system for novel substances, identified 27 new drugs across all of 2025. In the first five months of 2026 alone, the lab has already identified 23.

Some of what's showing up:

  • Xylazine. A veterinary tranquilizer often called "tranq" that has spread through the unregulated opioid supply nationwide. It's not an opioid, so naloxone doesn't reverse its sedative effects. It also causes severe wounds at injection sites.
  • Medetomidine. Another veterinary sedative, roughly 200 times more potent than xylazine, detected with increasing frequency in drug supplies across multiple cities. Naloxone doesn't reverse it, and withdrawal is severe and poorly understood.
  • Nitazenes. Synthetic opioids that can be more potent than fentanyl. They respond to naloxone but may require multiple doses, and they are only detectable with nitazene test strips.
  • Cychlorphine. A newly identified synthetic opioid described as up to 10 times stronger than fentanyl, now being used as a cutting agent in other illicit drugs without the buyer's knowledge.
  • Stimulant contamination. Cocaine, methamphetamine, and pressed pills sold as MDMA or other substances are increasingly being found to contain fentanyl, xylazine, or both. People who don't consider themselves opioid users are still at risk from a supply they have no way to verify by sight.

The pattern is consistent. As one adulterant becomes well-known and people learn to test for it, another one appears. Drug checking is a moving target, and the tools to do it well are exactly what just lost federal support.

⚠️ Critical Safety Note: Standard fentanyl test strips do not detect xylazine, medetomidine, or nitazenes. If you're testing for those, you need substance-specific strips or full lab analysis. Visual identification is never reliable — pills, powders, and crystals can contain anything regardless of how they look.

How to Reduce Overdose Risk: Drug Checking and Naloxone

The takeaway isn't that the overdose decline is fake. It's real, it's significant, and it happened because of work that has now been politically defunded. The current conditions mean the personal tools matter more than ever, because the public infrastructure backing them up is less reliable than it was a year ago.

  • Fentanyl test strips remain essential, but not sufficient. They detect fentanyl and most of its analogs, but not xylazine, medetomidine, or nitazenes.
  • Reagent testing adds another layer. Reagent kits help identify the primary substance in a sample and flag obvious adulteration. They catch things that test strips can miss. Using multiple reagents to cross-check is always recommended.
  • Mail-in lab analysis is the gold standard. When you need to know what's actually in a substance, including novel adulterants, full spectrometry from a lab is the most accurate option available outside of supervised consumption sites.
  • Naloxone should be within arm's reach. Carry it and know how to use it. It won't reverse xylazine or medetomidine sedation, but it will reverse the opioid component, which is usually what's killing people.
  • Never use alone if you can help it. If you must use alone, services like Never Use Alone (1-800-484-3731) can stay on the line with you.
  • Start low and go slow. Especially with a new batch, a new source, or anything pressed.
  • Visual identification is not reliable. Pills, powders, and crystals can contain anything. Color, shape, smell, and source reputation are not safety information.

The Layered Testing Approach:

  1. Fentanyl Test Strips: Screen any non-pharmaceutical substance for fentanyl and most analogs (Learn How to Test for Fentanyl)
  2. Reagent Kits: Identify the primary substance and flag obvious adulteration (Understand Our Test Kit Types)
  3. QTest Purity Kits: Determine the potency of what you actually have (QTest Basics)
  4. Mail-In Lab Analysis: Full spectrometry for definitive identification, including novel adulterants (Transparency Testing Lab Services)

Naloxone: Keep it on you and know how to use it — it's the single tool most directly responsible for the overdose decline.

The Future of Overdose Prevention

The three-year drop in overdose deaths is the most encouraging news in over a decade of drug policy reporting. It happened because harm reduction works. Now, the question is whether the trend continues.

The infrastructure that produced it is now operating under federal guidance that treats harm reduction as incompatible with public policy, while the drug supply continues to introduce substances that the existing tools weren't designed to detect. State and local programs, opioid settlement funds, and community-based organizations will absorb some of the gap, but not all of it.

The data confirms what harm reduction advocates have argued for years: when people who use drugs have access to naloxone, drug checking, and treatment, fewer of them die. Federal policy is now moving in the opposite direction, and the drug supply isn't standing still. The tools that drove the decline are the same tools that matter now, and they remain available regardless of which way federal funding shifts.

Stay safe, stay informed. Explore the most accurate test kits on the market at BunkPolice.com or send samples for full lab analysis at TransparencyTesting.com.

Frequently Asked Questions

Why are drug overdose deaths declining in 2025 and 2026?

The decline is broad-based and tied to harm reduction infrastructure: widespread naloxone distribution, fentanyl test strips, drug checking services, expanded treatment access, opioid settlement funding, and shifts in the unregulated drug supply itself. States that invested earliest in harm reduction (Oregon, North Carolina, New York, Alabama) are seeing the steepest declines.

What did SAMHSA change about harm reduction funding?

In late April 2026, SAMHSA issued updated guidance restricting federal grant recipients from using funds for fentanyl test strips and other harm reduction supplies, calling them "incompatible with Federal laws." For many small, often volunteer-powered programs, federal grants are the full budget — not a small piece of it.

Do fentanyl test strips detect xylazine or nitazenes?

No. Standard fentanyl test strips detect fentanyl and most of its analogs, but they do not detect xylazine, medetomidine, or nitazenes. Nitazene-specific test strips exist, and full mail-in lab analysis remains the most reliable way to identify novel adulterants.

Will naloxone reverse a xylazine or medetomidine overdose?

Naloxone will not reverse the sedative effects of xylazine or medetomidine — those aren't opioids. But it will reverse the opioid component of a mixed overdose, which is usually what's killing people. Always administer naloxone in a suspected overdose, even if you think other substances are involved.

Why does testing matter if I'm not using opioids?

Stimulants like cocaine and methamphetamine, as well as pressed pills sold as MDMA, Adderall, or Xanax, are increasingly being found to contain fentanyl, xylazine, or both. People who don't consider themselves opioid users are still at risk from a supply they have no way to verify by sight. Fentanyl test strips work on any non-pharmaceutical substance.

Related Resources

The Tools That Drove the Decline Are Still Available.

Federal funding may be shifting, but the personal tools that save lives — fentanyl test strips, reagent kits, lab analysis — remain in your hands. Stock up while the supply gets less predictable.

Shop Test Kits at Bunk Police → Submit a Sample for Lab Analysis →

Free shipping on orders over $75 | Discreet packaging | Ships fast

Sources